Sirolimus News and Research

RSS

New trend in treating heart disease in diabetics - angioplasty using the Cypher Sirolimus-eluting coronary stent

The World Health Organisation has predicted an increase in the worldwide prevalence of diabetes of epidemic proportions . Eighty percent of people with diabetes will die from cardiovascular complications -- stroke and/or coronary heart disease (CHD).

12 May 2005

Coronary artery stents that release medication appear more effective than traditional stents for patients with heart attack

A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA.

3 May 2005

Drug eluting stents as effective as vascular brachytherapy in preventing restenosis

After angioplasty is performed to widen clogged arteries, surgeons frequently use tiny wire-mesh tubes called stents to keep blood vessels open. But despite stenting, scar tissue can form to create new blockages -- a process called in-stent restenosis (ISR).

7 Mar 2005

Sirolimus drug-coated stent causes less inflammation than bare metal stents

In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill.

11 Nov 2004

Early reports of thrombosis after insertion of drug-eluting stent

Authors of a research letter in this week’s issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy.

21 Oct 2004

Drug-eluting stents (DES), increasingly used in coronary angioplasty, have benefits over bare-metal stents

A pooled analysis of 11 previously published trials provides evidence that drug-eluting stents (DES)—increasingly used in coronary angioplasty—have benefits over bare-metal stents (BMS) by reducing the need for later revascularisation and reducing the risk of cardiac events

15 Aug 2004

Sirolimus-based therapy following early cyclosporine withdrawal improves transplanted kidney structure and function

Kidney histology and function three years after transplantation are better in kidney-transplant patients who remain on sirolimus-based therapy following early withdrawal of cyclosporine than in patients who continue on this calcineurin inhibitor, according to a new study published in the American Journal of Transplantation.

11 Jun 2004

New stent appears safe and effective for preventing arteries from reclosing in coronary heart disease patients

A new stent appears safe and effective for preventing arteries from reclosing in coronary heart disease patients, based on one-year results of the first human trial using this stent reported in today’s rapid access issue of Circulation: Journal of the American Heart Association.

6 May 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004

Patients with coronary artery blockages can be treated safely using drug coated stents

The researchers followed 155 consecutive patients treated with multiple sirolimus-eluting stents between April 2002 and March 2003. Each patient had at least two lesions blocking blood flow in different coronary arteries. Earlier studies have demonstrated that patients with a single, simple artery narrowing held open with a sirolimus-eluting stent are less likely to need retreatment than similar patients who received a bare metal stent. However, those studies excluded patients with complex or multiple artery lesions.

6 Apr 2004

Cordis Cardiology receives warning from the U.S. Food and Drug Administration

Cordis Cardiology, a division of Cordis Corporation, a Johnson & Johnson Company, reported today that it received a warning letter from the U.S. Food and Drug Administration (FDA) regarding FDA's observations concerning the Good Manufacturing Practice (GMP) regulations.

5 Apr 2004